Insulin analogues

Lancet

Volumn 349, Issue 9044, 1997, Pages 47-51

  Barnett, A H ^a   Owens, D R ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; METFORMIN; NOVOSOL BASAL; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; VASCULAR DISEASE;

EID: 0031033686     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)06032-1     Document Type: Article

References (39)

1. B Zinman The physiological replacement of insulin: an elusive goal N Engl J Med 321 1989 363 370
2. J Brange DR Owens S Kang A Vølund Monomeric insulins and their experimental and clinical implications Diabet Care 13 1990 923 954
3. DR Owens Human insulin: clinical pharmacology studies in normal man. MD thesis 1986 MTP Press Lancaster, UK
4. J Brange U Ribel JF Hansen Monomeric insulins obtained by protein engineering and their medical implications Nature 333 1988 679 682
5. S Kang J Brange A Burch A V0lund DR Owens Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans Diabet Care 14 1991 942 948
6. JA Galloway RE Chance Approaches to insulin analogues SM Marshall PD Home The diabetes annual. Vol 8 1994 Elsevier Amsterdam 277 297
7. WN Shaw KSE Su Biological aspects of a new human insulin analog: [Lys(B28), Pro(B29)]-human insulin Diabetes 40 suppl 1 1991 464A
8. DC Howey RR Bowsher RL Brunelle JR Woodworth [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin Diabetes 43 1994 396 402
9. AH Pekar BH Frank Conformation of pro-insulin: a comparison of insulin and pro-insulin self-association at neutral pH Biochemistry J 11 1972 4013 4016
10. B29 human insulin Structure 3 1995 615 622
11. B28) on meal-related plasma glucose excursions in type 1 diabetic subjects Diabet Care 14 1991 571 577
12. B28) in healthy subjects Diabet Care 14 1991 1057 1065
13. FS Nielsen LN Jørgensen M Ipsen AI Voldsgaard H-H Parving Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regime Diabetologia 38 1995 592 598
14. K Drejer The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake Diabet/Metabol Rev 8 1992 259 286
15. RD DiMarchi RE Chance HB Long JE Shields LJ Slieker Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor-I Horm Res 41 suppl 2 1994 93 96
16. LJ Slieker K Sundell Modifications in the 28–29 position of the insulin B-chain after binding to the IGF-I receptor with minimal effect on insulin receptor binding Diabetes 40 suppl 1 1991 168A
17. BF Hansen GM Danielsen K Drejer Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency Biochem J 315 1996 271 279
18. LJ Slieker GS Brooke RE Chance Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics D Le Roith Raizada MK 1994 Plenum Press New York 25 32
19. LJ Slieker PL Surface In vitro analysis of Lys(B28), Pro(B29) human insulin (LY275585): comparison to human insulin and Asp (B10) human insulin in terms of dissociation kinetics from the HepG2 insulin receptor. Preclinical pharmacology report 11. Data on file, Eli Lilly and Company.
20. J Zimmermann A 12-month chronic toxicity study of LY275585 (human insulin analog) administered subcutaneously to Fischer 344 Rats Diabetes 4 suppl 1 1994 166A
21. L Heinemann T Heise LN Jørgensen AAR Starke Action profile of the rapid acting insulin analogue: human insulin B28Asp Diabetic Med 10 1993 535 539
22. S Jørgensen A Vaag L Langkjaer P Hougaard J Markussen NovoSol Basal: pharmacokinetics of a novel long acting insulin analogue BMJ 299 1989 415 419
23. M Talaulicar B Willms Rosskamp HOE 901, ein neues Insulinanalogon, zur Substitution des basalen Insulin-bedarfs bei Typ-1-Diabetes Diabet Stoffwechsel 5 1996 3 6
24. PA Coates S Mukherjee S Luzio Pharmacokinetics of a “long-acting” human insulin analogue (HOE901) in healthy subjects Diabetes 44 suppl 1 1995 130A
25. J Markussen S Havelund P Kurtzhals Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs Diabetologia 39 1996 281 288
26. U Ribel P Hougaard K Drejer AR Sørenson Insulin analogues and human insulin: equivalent in vivo biological activity despite different in vitro potencies Diabetes 39 1990 1033 1039
27. DN Brems LA Alter MJ Beckage Altering the association properties of insulin by amino acid replacement Prot Engineer 5 1995 527 533
28. E Torlone C Fanelli AM Rambotti Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM Diabetologia 37 1994 713 720
29. E Torlone S Pampanelli C Lalli Postprandial glycemic control in IDDM after sc. LysPro analogue or human regular insulin, alone or mixed with NPH Diabetologia 38 suppl 1 1995 A190
30. MR DeFelippis DL Bakaysa KM Youngman J Radziuk BH Frank Preparation and characterization of neutral protamine lispro (NPL) suspension Diabetes 45 suppl 12 1996 74A
31. J Anderson S Symanowski R Brunelle Safety of [Lys(B28), Pro(B29)] human insulin analog in long-term clinical trials Diabetes 43 suppl 1 1994 61A
32. A Pfützner E Küstner T Forst Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes Exp Clin Endocrinol Diabet 104 1996 25 30
33. R Rowe JH Anderson E Gale A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen Diabetes 45 suppl 2 1996 71A
34. JH Anderson RL Brunelle L Vignati Insulin lispro compared to regular insulin in a crossover study involving 1037 patients with type I diabetes Diabetes 44 suppl 1 1995 228A
35. SE Fineberg S Fineberg JH Anderson M Birkett Does the use of short-acting (LysPro) human insulin in insulin naive patients augment the insulin immune response or differ between type I and type II patients? Diabetes 44 suppl 1 1995 23A
36. JH Anderson L Vignati RL Brunelle B Boggs Therapy of type II diabetes with insulin LisPro, a rapidly absorbed insulin analog Diabetologia 37 suppl 1 1994 A169
37. JG Kotsanos L Vignati W Huster CM Andrejasich JA Galloway JH Anderson Quality of life in patients with type I diabetes treated with rapid-acting insulin analog versus regular insulin: results from a multinational clinical trial 15th International Diabetes Federation Congress 43 suppl 1 1994 155A
38. PM Round KJ Olsen PD Home Improved blood glucose control with insulin analogue B28-ASP Diabetologia 39 suppl 1 1996 A24
39. E Torlone S Pampanelli C Lalli Effects of short-acting insulin analogue [LYS(B28), PRO(B29)] on post-prandial blood glucose control in IDDM Diabet Care 19 1996 945 952